TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $208
H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $221
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
Krystal Biotech Analyst Ratings
H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $221
Buy Rating Affirmed for Krystal Biotech Following Promising KB301 Study Results
Stifel Maintains Krystal Biotech(KRYS.US) With Buy Rating
Stifel Nicolaus Keeps Their Buy Rating on Krystal Biotech (KRYS)
Barclays Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $63
Analysts' Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100
Avidity Biosciences Analyst Ratings
Evercore Maintains Avidity Biosciences(RNA.US) With Buy Rating, Cuts Target Price to $53
Evercore ISI Trims Price Target on Avidity Biosciences to $53 From $54, Keeps Outperform Rating
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Raises Target Price to $100
CCORF Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $85
Evercore ISI Lifts Price Target on Krystal Biotech to $206 From $201, Keeps Outperform Rating
Buy Rating for Arcellx Inc: Operational Efficiencies and Market Advantages Over Legend/JnJ Propel Positive Outlook
Buy Rating on Merus Backed by Strong Clinical Advantages and Market Positioning
Piper Sandler Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $57